TWST News and Press, Twist Bioscience Corporation

Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...

2024-07-16 07:00:00 ET Summary Small-cap stocks struggled in the first half of 2024 due to economic concerns and higher interest rates, lagging behind broader market indexes. The outlook for small caps in the second half depends on timely interest rate cuts and stable economic gro...

2024-07-12 14:30:06 ET More on Exact Sciences: Exact Sciences: Still No Reason To Own Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript Exact Sciences initiated at sector outperform at Scotiabank on advanced diagnostics Exact Sciences gains a...

Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...

Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...

NGS-verified synthetic control covers 99.9% of HA and NA genome regions Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its growing port...

2024-06-28 07:15:04 ET Barclays analyst issues OVERWEIGHT recommendation for TWST on June 28, 2024 05:29AM ET. The previous analyst recommendation was Overweight. TWST was trading at $47.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A 2A R with in vivo tumor suppressing activity TB206-001 available for out-licensing Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering...

2024-06-05 14:24:49 ET More on Twist Bioscience Twist Bioscience: NGS Is Taking Off Twist Bioscience Corporation (TWST) Q2 2024 Earnings Call Transcript Twist Bioscience launches MGF product, stock climbs 10% Twist Bioscience up 8% on 2024 revenue guidance ra...

Twist Bioscience Corporation (NASDAQ: TWST) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 11.58% on the day to $52.42. Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-bas...